1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Hangzhou Tigermed Consulting Co., Ltd
  6. Summary
    300347   CNE100001KV8

HANGZHOU TIGERMED CONSULTING CO., LTD

(300347)
  Report
End-of-day quote Shenzhen Stock Exchange  -  2022-07-05
127.45 CNY   +0.74%
07/04Tranche Update on Hangzhou Tigermed Consulting Co., Ltd's Equity Buyback Plan announced on February 13, 2022.
CI
06/27Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes
CI
05/25Hangzhou Tigermed Consulting Co., Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 31 May 2022
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shenzhen Stock Exchange
06/30/2022 07/01/2022 07/04/2022 07/05/2022 07/06/2022 Date
114.45 115.3 121.89 126.51 127.45 Last
7021555 4896822 11187310 9492627 12653800 Volume
+3.11% +0.74% +5.72% +3.79% +0.74% Change
Estimated financial data (e)
Sales 2022 7 013 M 1 045 M 1 045 M
Net income 2022 2 937 M 438 M 438 M
Net cash position 2022 11 798 M 1 759 M 1 759 M
P/E ratio 2022 37,8x
Yield 2022 0,53%
Sales 2023 8 950 M 1 334 M 1 334 M
Net income 2023 3 657 M 545 M 545 M
Net cash position 2023 14 024 M 2 091 M 2 091 M
P/E ratio 2023 30,4x
Yield 2023 0,63%
Capitalization 106 B 15 729 M 15 729 M
EV / Sales 2022 13,4x
EV / Sales 2023 10,2x
Nbr of Employees -
Free-Float 68,5%
More Financials
Company
Hangzhou Tigermed Consulting Co, Ltd. specialises in providing professional services to pharmaceutical and biotech companies. The group supports its clients in all processes of clinical development and product commercialization. Net sales break down by activity as follows: - provision of clinical trial services and related technological services (51.8%); - provision of clinical research consulting services (48.2%). 
More about the company
Ratings of Hangzhou Tigermed Consulting Co., Ltd
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about HANGZHOU TIGERMED CONSULTING CO., LTD
07/04Tranche Update on Hangzhou Tigermed Consulting Co., Ltd's Equity Buyback Plan announced..
CI
06/27Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes
CI
05/25Hangzhou Tigermed Consulting Co., Ltd Announces 2021 Final Profit Distribution Plan to ..
CI
05/20Hangzhou Tigermed Consulting Co., Ltd Approves Final Dividend to for the Year Ended Dec..
CI
04/28Hangzhou Tigermed Consulting Co. Ltd. Announces Ordinary Final Dividend for the Year En..
CI
04/27Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to HK$115.13 From HK$134.75,..
MT
04/27Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to 125.87 Yuan From 147.33 Y..
MT
04/26Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the First Quarter En..
CI
04/07LTZ Therapeutics announced that it has received $17 million in funding from K2VC, Qimin..
CI
04/01Tranche Update on Hangzhou Tigermed Consulting Co., Ltd's Equity Buyback Plan announced..
CI
03/28Hangzhou Tigermed Consulting Co., Ltd Proposes Final Ordinary Dividend for the Year End..
CI
03/14Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to HK$134.75 From HK$141.67,..
MT
03/14Nomura Adjusts Tigermed's Price Target to 147.33 Yuan From 154.89 Yuan, Keeps at Buy
MT
03/11Hangzhou Tigermed Logs Higher Preliminary Earnings in 2021; Shenzhen Shares Jump 4%
MT
03/10Hangzhou Tigermed Posts Over 100% Surge in Preliminary January-February Revenue; Shenzh..
MT
More news
News in other languages on HANGZHOU TIGERMED CONSULTING CO., LTD
06/27Hangzhou Tigermed Consulting Co., Ltd annonce des changements de direction
05/25Hangzhou Tigermed Consulting Co., Ltd annonce la mise en œuvre du plan final de distrib..
05/20Hangzhou Tigermed Consulting Co., Ltd approuve le dividende final pour l'exercice clos ..
04/28Hangzhou Tigermed Consulting Co. Ltd. annonce un dividende final ordinaire pour l'exerc..
04/26Hangzhou Tigermed Consulting Co., Ltd annonce ses résultats pour le premier trimestre c..
More news
Analyst Recommendations on HANGZHOU TIGERMED CONSULTING CO., LTD
More recommendations
Chart HANGZHOU TIGERMED CONSULTING CO., LTD
Duration : Period :
Hangzhou Tigermed Consulting Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HANGZHOU TIGERMED CONSULTING CO., LTD
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Last Close Price 127,45 CNY
Average target price 147,13 CNY
Spread / Average Target 15,4%
EPS Revisions
Managers and Directors
Xiao Chun Cao Chief Financial Officer, Executive Director & GM
Hao Wu Co-President & Executive Director
Xiao Ping Ye Chairman
Bing Hui Zhang Chairman-Supervisory Board
Bi Yun Zheng Independent Director
Sector and Competitors
1st jan.Capi. (M$)
HANGZHOU TIGERMED CONSULTING CO., LTD-0.27%15 729
MODERNA, INC.-37.18%63 467
LONZA GROUP AG-28.02%41 871
IQVIA HOLDINGS INC.-23.44%40 884
SEAGEN INC.13.28%32 237
CELLTRION, INC.-5.81%19 739